Not independent
Tenure on this board
3.1 yrs
Meeting calendar
COCH · Special meeting · Wednesday, November 26, 2025
Envoy Medical Inc
7 nominees · 2 ballot items.
Issuance of Private Placement Warrants and underlying Class A Common Stock to Nasdaq Listing Rule 5635(d) and adjournment of the Special Meeting to solicit additional proxies.
Market cap
$502M
1Y TSR
+5.3%
Board grade
C-
Record date
Oct 2, 2025
Filing
DEF 14A
Meeting concluded · Nov 26, 2025
Follow how the vote landed and what changed on Envoy Medical Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Issuance Proposal
ManagementBoard: FORApprove the issuance of Private Placement Warrants to purchase up to 5,725,206 shares of Class A Common Stock and the issuance of Class A Common Stock underlying such warrants, plus issuance of Placement Agent Warrants to purchase up to 143,130 shares (and additional warrants equal to 7.5% of underlying shares) in connection with the September 2025 offering, to comply with Nasdaq Listing Rule 5635(d).
- 2
Adjournment Proposal
ManagementBoard: FORApprove adjournment of the Special Meeting to permit further solicitation of proxies if necessary to obtain a quorum or enough votes for Proposal 1.
Director elections
Nominees on the ballot7
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
3.1 yrs
Independent
Tenure on this board
2.4 yrs
Independent
Tenure on this board
5.7 yrs
Independent
Tenure on this board
3.1 yrs
Independent
Tenure on this board
3.1 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 9.9% | 7,650,000 | $6M |
| 2 | Bleichroeder LP | 8.1% | 6,250,000 | $5M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.1% | 880,214 | $697K |
| 4 | DSG Capital Advisors, LLC | 0.8% | 625,000 | $474K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 0.6% | 429,274 | $340K |
| 6 | Focus Partners Wealth | 0.6% | 425,310 | $337K |
| 7 | VANGUARD FIDUCIARY TRUST CO | 0.4% | 296,679 | $235K |
| 8 | Arcus Capital Partners, LLC | 0.2% | 187,573 | $149K |
| 9 | ExodusPoint Capital Management, LP | 0.2% | 182,354 | $144K |
| 10 | UBS Group AG | 0.2% | 180,361 | $143K |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Envoy Medical Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Entera Bio LtdENTX
Special meeting·Nov 24, 2026·$495M
Angiodynamics IncANGO
Annual meeting·Nov 17, 2026·$512M
Tilray Brands IncTLRY
Annual meeting·Nov 18, 2026·$402M
Wave Life Sciences IncWVE
Annual meeting·Nov 12, 2026·$633M
Rezolute IncRZLT
Annual meeting·Dec 2, 2026·$370M
Galectin Therapeutics IncGALT
Annual meeting·Dec 3, 2026·$322M
Reference
Frequently asked questions
- When is the Envoy Medical Inc 2025 special meeting?
- Envoy Medical Inc (COCH) holds its 2025 special shareholder meeting on Wednesday, November 26, 2025.
- What is the record date for the Envoy Medical Inc 2025 meeting?
- The record date for the Envoy Medical Inc 2025 meeting is Thursday, October 2, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Envoy Medical Inc's 2025 meeting?
- The board is presenting 7 director nominees at the Envoy Medical Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Envoy Medical Inc 2025 meeting?
- Shareholders will vote on 2 proposals at the Envoy Medical Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.